Rani Therapeutics Holdings (RANI) Depreciation & Amortization (CF) (2020 - 2026)

Rani Therapeutics Holdings' Depreciation & Amortization (CF) history spans 7 years, with the latest figure at $161000.0 for Q1 2026.

  • On a quarterly basis, Depreciation & Amortization (CF) fell 35.86% to $161000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was $810000.0, a 21.44% decrease, with the full-year FY2025 number at $900000.0, down 12.45% from a year prior.
  • Depreciation & Amortization (CF) came in at $161000.0 for Q1 2026, down from $186000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $266000.0 in Q4 2024, with the low at $111000.0 in Q1 2022.
  • Historically, Depreciation & Amortization (CF) has averaged $203470.6 across 5 years, with a median of $218000.0 in 2023.
  • Biggest five-year swings in Depreciation & Amortization (CF): skyrocketed 69.37% in 2023 and later plummeted 35.86% in 2026.
  • Year by year, Depreciation & Amortization (CF) stood at $174000.0 in 2022, then surged by 30.46% to $227000.0 in 2023, then rose by 17.18% to $266000.0 in 2024, then crashed by 30.08% to $186000.0 in 2025, then dropped by 13.44% to $161000.0 in 2026.
  • Business Quant data shows Depreciation & Amortization (CF) for RANI at $161000.0 in Q1 2026, $186000.0 in Q4 2025, and $223000.0 in Q3 2025.